XML 107 R66.htm IDEA: XBRL DOCUMENT v3.3.1.900
SUBSEQUENT EVENTS (Details)
$ in Thousands
1 Months Ended 9 Months Ended 12 Months Ended
Mar. 26, 2015
patent
Mar. 24, 2015
patent
Mar. 06, 2015
USD ($)
shares
Apr. 30, 2015
shares
Mar. 31, 2015
USD ($)
ft²
shares
Dec. 31, 2013
Sep. 30, 2015
USD ($)
shares
Dec. 31, 2014
USD ($)
shares
Jul. 31, 2014
shares
SUBSEQUENT EVENTS                  
Principal amount converted | $             $ 5,000    
Stock-based compensation                  
Options granted (in shares)             1,197,452    
Restricted stock granted (in shares)             194,694    
Stockholders' Equity Note [Abstract]                  
Common stock split ratio       0.144927536          
Office and research facility operating lease                  
Lease                  
Area of Real Estate Property | ft²         19,335        
Term of lease extension option         5 years        
Office and research facility operating lease | Delivery of expansion space with substantial completion of certain improvements                  
Lease                  
Lease term         5 years        
Amendment to office and research facility operating lease                  
Lease                  
Area of Real Estate Property | ft²         9,660        
2014 Stock Incentive Plan                  
Stock-based compensation                  
Maximum number of shares authorized for issuance (in shares)       2,700,000         525,700
Restricted stock                  
Stock-based compensation                  
Restricted stock granted (in shares)               10,869  
Purdue Pharma, L. P. patent infringement suit, District of Delaware                  
Contingencies                  
Number of patents asserted to have been infringed | patent   4              
Purdue Pharma, L. P., patent infringement suit, District of Massachusetts                  
Contingencies                  
Number of patents asserted to have been infringed | patent 4                
Redeemable Convertible Preferred Stock | Mandatory conversion, initial public offering | Minimum                  
SUBSEQUENT EVENTS                  
Gross proceeds from sale of stock | $               $ 50,000  
Series D convertible redeemable preferred stock                  
SUBSEQUENT EVENTS                  
Cash consideration from issuance of preferred stock | $         $ 45,000        
6.0% Convertible promissory notes                  
SUBSEQUENT EVENTS                  
Principal amount converted | $         $ 5,000        
Common stock                  
Stockholders' Equity Note [Abstract]                  
Common stock split ratio           0.5      
Subsequent events | Office and research facility operating lease                  
Lease                  
Area of Real Estate Property | ft²         19,335        
Term of lease extension option         5 years        
Subsequent events | Office and research facility operating lease | Delivery of expansion space with substantial completion of certain improvements                  
Lease                  
Lease term         5 years        
Subsequent events | Amendment to office and research facility operating lease                  
Lease                  
Area of Real Estate Property | ft²         9,660        
Subsequent events | 2014 Stock Incentive Plan                  
Stock-based compensation                  
Maximum number of shares authorized for issuance (in shares)         1,087,005        
Subsequent events | Employee stock options                  
Stock-based compensation                  
Options granted (in shares)         638,095        
Vesting period         4 years        
Period from grant date to expiration         10 years        
Subsequent events | Restricted stock                  
Stock-based compensation                  
Restricted stock granted (in shares)       194,694          
Subsequent events | Restricted stock | Vested upon grant                  
Stock-based compensation                  
Restricted stock granted (in shares)       97,347          
Subsequent events | Restricted stock | Vesting in monthly installments                  
Stock-based compensation                  
Restricted stock granted (in shares)       97,347          
Vesting period       3 years          
Subsequent events | Purdue Pharma, L. P. patent infringement suit, District of Delaware                  
Contingencies                  
Number of patents asserted to have been infringed | patent   4              
Subsequent events | Purdue Pharma, L. P., patent infringement suit, District of Massachusetts                  
Contingencies                  
Number of patents asserted to have been infringed | patent 4                
Subsequent events | Private Placement | Investors | Series D convertible redeemable preferred stock                  
SUBSEQUENT EVENTS                  
Issuance of stock (in shares)     41,666,667            
Aggregate consideration | $     $ 50,000            
Cash consideration from issuance of preferred stock | $     45,000            
Subsequent events | Conversion of convertible notes into convertible preferred stock | Investors | 6.0% Convertible promissory notes                  
SUBSEQUENT EVENTS                  
Principal amount converted | $     $ 5,000            
Subsequent events | Conversion of convertible notes into convertible preferred stock | Investors | 6.0% Convertible promissory notes | Series D convertible redeemable preferred stock                  
SUBSEQUENT EVENTS                  
Number of shares of stock into which debt was converted (in shares)     4,166,667